首页|期刊导航|中国海洋大学学报(自然科学版)|S1PR2拮抗剂的设计合成及逆转结直肠癌5-FU耐药活性研究

S1PR2拮抗剂的设计合成及逆转结直肠癌5-FU耐药活性研究OA

Design,Synthesis and Evaluation of S1PR2 Antagonists for Reversing 5-FU Resistance in Colorectal Cancer

中文摘要英文摘要

本文针对结直肠癌细胞(HT29,SW620)对 5-氟尿嘧啶(5-Fluorouracil,5-FU)的耐药性问题,进行了新型5-FU耐药逆转剂研究.基于S1PR2拮抗剂JTE-013可通过下调二氢嘧啶脱氢酶(Dihydropyrimidine dehydrogenase,DPD)的表达,减少5-FU降解从而逆转5-FU耐药的机制,本研究设计并合成了19个结构新颖的JTE-013衍生物,并系统评价了它们在两株5-FU耐药结直肠癌细胞(HT29/5-FU、SW620/5-FU)中的逆转活性.结果表明,化合物12j在 HT29/5-FU细胞中单药半数抑制浓度(Half maximal inhibitory concentration,IC50)为(255.80±0.91)μmol/L,与20 μmol/L 5-FU联用时的耐药逆转活性(Half maximal effect concentration,EC50)为(12.12±0.34)μmol/L,其5-FU耐药逆转活性较先导化合物JTE-013(EC50=(68.62±1.34)μmol/L)提高约5.7倍.此外,在20 μmol/L 12j与5-FU联合用药条件下,SW620/5-FU和HT29/5-FU细胞的5-FU耐药逆转倍数分别达到72.6和39.7.本研究表明,化合物12j具有显著优于JTE-013的5-FU耐药逆转效果,为克服结直肠癌5-FU耐药提供了有潜力的先导结构.

To develop novel 5-fluorouracil(5-FU)resistance reversal agents against 5-FU resistance in colorectal cancer cells(HT29,SW620).Based on the mechanism that the S1PR2 antagonist JTE-013 reverses 5-FU resistance via downregulating dihydropyrimidine dehydrogenase(DPD)expression and re-ducing 5-FU degradation,19 structurally novel JTE-013 derivatives were designed and synthesized.Their 5-FU resistance reversal activities were systematically assessed in two 5-FU-resistant colorectal cancer cell lines(HT29/5FU,SW620/5FU).Compound 12j showed a single-agent IC50 of(255.80±0.91)μmol/L in HT29/5FU cells,and an EC50 of(12.12±0.34)μmol/L when combined with 20 μmol/L 5-FU.Its 5-FU resistance reversal activity was approximately 5.7-fold higher than that of the lead compound JTE-013(EC50=(68.62±1.34)μmol/L).Moreover,under the combined administra-tion of 20 μmol/L 12j and 5-FU,the 5-FU resistance reversal folds reached 72.6 in SW620/5FU cells and 39.7 in HT29/5FU cells,respectively.In this study,compound 12j displays markedly better 5-FU resistance reversal efficacy than JTE-013,offering a promising lead structure for overcoming 5-FU re-sistance in colorectal cancer.

白若欣;李冬洋;姜磊磊;万升标

中国海洋大学 医药学院,海洋药物教育部重点实验室,山东 青岛 266003中国海洋大学 医药学院,海洋药物教育部重点实验室,山东 青岛 266003中国海洋大学 医药学院,海洋药物教育部重点实验室,山东 青岛 266003中国海洋大学 医药学院,海洋药物教育部重点实验室,山东 青岛 266003

医药卫生

结直肠癌5-FU耐药S1PR2拮抗剂JTE-013逆转耐药

colorectal cancer5-FU resistanceS1PR2 antagonistJTE-013resistance reversal

《中国海洋大学学报(自然科学版)》 2026 (9)

121-130,10

国家自然科学基金项目(82273777)中央高校基本科研业务费专项(202461065)资助Supported by the National Natural Science Foundation of China(82273777)the Fundamental Research Funds for the Central Univer-sities(202461065)

10.16441/j.cnki.hdxb.20250279

评论